Cardiovascular Division, Hospital of the University of Pennsylvania and Cardiovascular Institute, University of Pennsylvania, Philadelphia, PA, USA.
J Intern Med. 2011 Jan;269(1):94-106. doi: 10.1111/j.1365-2796.2010.02297.x. Epub 2010 Nov 5.
Lipoprotein-associated phospholipase A2 (Lp-PLA₂) is at the crossroads of lipid metabolism and the inflammatory response. It is produced by inflammatory cells, bound to LDL and other lipoproteins, and once in the arterial wall facilitates hydrolysis of phospholipids. Elevated serum levels of Lp-PLA₂ have been associated with increased cardiovascular risk in healthy populations and in patients with known vascular disease. Here, we review the role of Lp-PLA₂ in the development of atherosclerosis and progression to unstable disease, the utility of Lp-PLA₂ as a risk predictor for coronary and carotid events and the potential clinical benefit of pharmacologic inhibition of Lp-PLA₂.
脂蛋白相关磷脂酶 A2(Lp-PLA₂)处于脂质代谢和炎症反应的交汇点。它由炎症细胞产生,与 LDL 和其他脂蛋白结合,一旦进入动脉壁,就会促进磷脂水解。在健康人群和已知血管疾病患者中,血清 Lp-PLA₂水平升高与心血管风险增加相关。在这里,我们回顾了 Lp-PLA₂在动脉粥样硬化发展和不稳定疾病进展中的作用,Lp-PLA₂作为冠状动脉和颈动脉事件风险预测因子的效用,以及 Lp-PLA₂药理抑制的潜在临床益处。